Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: Findings from the EUROASPIRE III survey

Atherosclerosis

Volumn 231, Issue 2, 2013, Pages 300-307

  Reiner, Željko ^a   De Bacquer, Dirk ^b   Kotseva, Kornelia ^c   Prugger, Christof ^d   De Backer, Guy ^b   Wood, David ^c  

^a KBC Zagreb   (Croatia)

^b GHENT UNIVERSITY   (Belgium)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Cholesterol; Coronary heart disease; EUROASPIRE; HDL cholesterol; LDL cholesterol; Secondary prevention; Statins

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; EUROPE; FEMALE; FINLAND; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LITHUANIA; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTICENTER STUDY; PRIORITY JOURNAL;

CHOLESTEROL; CORONARY HEART DISEASE; EUROASPIRE; HDL-CHOLESTEROL; LDL-CHOLESTEROL; SECONDARY PREVENTION; STATINS;

ADOLESCENT; ADULT; AGED; CHOLESTEROL; CORONARY DISEASE; DYSLIPIDEMIAS; EUROPE; FEMALE; HEALTH SURVEYS; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; YOUNG ADULT;

EID: 84888120293     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.09.020     Document Type: Article

References (38)

1. Merkler M., Reiner Ž. The burden of hyperlipidaemia and diabetes in cardiovascular diseases. Fundam Clin Pharmacol 2007, 21:1-3.
2. Graham I., Cooney M.T., Bradley D., Dudina A., Reiner Ž. Dyslipidemias in the prevention of cardiovascular disease: risks and causality. Curr Cardiol Rep 2012, 14:709-720.
3. Perk J., De Backer G., Gohlke H., et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Atherosclerosis 2012, 223:1-68.
4. Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681. 'Cholesterol Treatment Trialists' (CTT) Collaboration.
5. Reiner Z., Catapano A.L., De Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818.
6. Harchaoui K.E.L., Visser M.E., Kastelein J.J.P., Stroes E.S., Dallinga-Thie G.M. Triglycerides and cardiovascular risk. Curr Cardiol Rev 2009, 5:216-222.
7. Pyorala K., De Backer G., Graham I., Poole-Wilson P., Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 1994, 110:121-161.
8. Vanuzzo D., Pilotto L., Ambrosio G.B., et al. Potential for cholesterol lowering in secondary prevention of coronary heart disease in Europe: findings from EUROASPIRE study. European action on secondary prevention through intervention to reduce events. Atherosclerosis 2000, 153:505-517.
9. Wood D., De Backer G., Faergeman O., et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other societies on coronary prevention. Atherosclerosis 1998, 140:199-270.
10. Kotseva K., Stagmo M., De Bacquer D., De Backer G., Wood D. Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis 2008, 197:710-717. EUROASPIRE II Study Group.
11. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis 2003, 171:145-155.
12. Kotseva K., Wood D., De Backer G., et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009, 16:121-137. EUROASPIRE Study Group.
13. Pedersen T.R., Faergeman O., Kastelein J.J., et al. Incremental Decrease in End Points through Aggressive Lipid Lowering (IDEAL) Study Group high-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAm Med Assoc 2005, 294:2437-2445.
14. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. NEngl J Med 2005, 352:1425-1435.
15. Graham I., Atar D., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice. Atherosclerosis 2007, 194:1-44.
16. Reiner Z. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol 2013, 10:453-464.
17. Perreault S., Blais L., Lamarre D., et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 2005, 59:564-573.
18. Reiner Ž., Tedeschi-Reiner E. Prevalence and types of persistent dyslipidaemia in patients treated with statins. Croat Med J 2013, 54:339-345.
19. Reiner Ž., Mihatov Š., Miličić D., Bergovec M., Planinc D. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study). Eur J Cardiovasc Prev Rehabil 2006, 13:646-654. on behalf of The TASPIC-CRO Study Group Investigators.
20. Cooney M.T., Reiner Ž., Sheu W., et al. SURF - survey of risk factor management: first report of an international audit. Eur J Prev Cardiol 2012 Nov 19, 19. [Epub ahead of print].
21. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590. 'Cholesterol Treatment Trialists' (CTT) Collaborators.
22. Kotseva K., Wood D., De Backer G., et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009, 373:929-940.
23. Reiner Z., Sonicki Z., Tedeschi-Reiner E. Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. Atherosclerosis 2010, 213:598-603.
24. Reiner Ž., Sonicki Z., Tedeschi-Reiner E. The perception and knowledge of cardiovascular risk factors among medical students. Croat Med J 2012, 53:278-284.
25. Reiner Z., Sonicki Z., Tedeschi-Reiner E. Public perceptions of cardiovascular risk factors in Croatia: the PERCRO survey. Prev Med 2010, 51:494-496.
26. Zannad F., Dallongeville J., Macfadyen R.J., et al. Prevention of cardiovascular disease guided by total risk estimations - challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on Cardiovascular Pharmacology and Drug Therapy. Eur J Prev Cardiol 2012, 19:1454-1464.
27. Reiner Ž. How to improve cardiovascular diseases prevention in Europe?. Nutr Metab Cardiovasc Dis 2009, 19:451-454.
28. Parikh N.I., Pencina M.J., Wang T.J., et al. Increasing trends in incidence of overweight and obesity over 5 decades. Am J Med 2007, 120:242-250.
29. De Bacquer D., Dallongeville J., Heidrich J., et al. Management of overweight and obese patients with coronary heart disease across Europe. Eur J Cardiovasc Prev Rehabil 2010, 17:447-454.
30. Hulley S.B., Rosenman R.H., Bawol R.D., Brand R.J. Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. NEngl J Med 1980, 302:1383-1389.
31. Di Angelantonio E., Sarwar N., Perry P., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAm Med Assoc 2009, 302:1993-2000. Emerging Risk Factors Collaboration.
32. Fruchart J.C., Sacks F., Hermans M.P., et al. The residual risk reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008, 102:1K-34K.
33. Chapman M.J., Ginsberg H.N., Amarenco P., et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011, 332:1345-1361.
34. Watts G.F., Karpe F. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Heart 2011, 97:350-356.
35. Bruckert E., Labreuche J., Deplanque D., Touboul P.J., Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. JCardiovasc Pharmacol 2011, 57:267-272.
36. Lee M., Saver J.L., Towfighi A., Chow J., Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis 2011, 217:492-498.
37. Reiner Ž. Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol 2010, 24:19-28.
38. Reiner Ž. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: clinical update. Nutr Metab Cardiovasc Dis 2013, 23:799-807.